Mel Heyman: Past, Present and Future of ARFID

Recently, at the Georgia AAP Pediatrics by the Sea meeting, Mel Heyman presented a terrific lecture reviewing ARFID. This lecture delved into the historical backgrounds of eating disorders and described the subtypes of ARFID along with evaluation/management. This lecture was presented in honor of Stan Cohen who recently retired from our group. Here are many of the slides:

Related blog posts:

Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician.  Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure.  This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.

Avoidant/Restrictive Food Intake Disorder (ARFID) with Irritable Bowel Syndrome and with Inflammatory Bowel Disease

Last week, this blog highlighted a study regarding the prevalence of ARFID in pediatric neurogastroenterology (Prevalence of Avoidant/Restrictive Food Intake Disorders in Pediatric Neurogastroenterology).

Today, this post reviews a study with 955 adult patients from 4 prospective studies who had completed the IBS Quality of Life Instrument (IBS-QOL). The 3 questions constituting the food domain were used to identify patients with reported severe food avoidance and restriction.

Key findings:

  • In total, 13.2 % of the patients reported severe food avoidance and restriction, and in these patients all aspects of quality of life were lower (P < .01) and psychological, GI, and somatic symptoms were more severe (P < .05). 

The associated editorial provides a lot of information on ARFID in this setting.

Key points:

  • “The sine qua non of ARFID is a reduction in food intake, in terms of volume and/or variety, not primarily motivated by body image disturbance”
  • “Motivations behind changes in eating in ARFID need to be 1 or more of 3 prototypical presentations: (1) fear of aversive consequences (eg, IBS symptoms), (2) a lack of interest in eating or low appetite, and (3) sensitivity to sensory characteristics of food (eg, taste, texture, smell)”
  • “Weight suppression has similar deleterious health effects as is seen in anorexia nervosa, including cardiac abnormalities and bone mineral density loss”
  • “Up to 90% of patients in IBS reporting avoidance of specific foods”
  • “To identify presence of problematic avoidant/restrictive eating, there are ARFID measures validated with cutoffs (eg, the 9-item ARFID Screen;22,23 the PARDI-ARFID questionnaire).24 Nevertheless, more research is needed on the utility of these screening measures in IBS populations”

My take: Patients with ARFID and IBS need much more careful dietary counseling. So, it is important to consider the possibility of ARFID in this patient population.

Related article: E Yelencich et al. Clin Gastroenterol Hepatol 2022; 20: 1282-1289. Open Access PDF: Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease In this cross-sectional study of adults with IBD, 28/161 (17%) had a positive ARFID risk score (>/=24). Most participants (92%) reported avoiding 1 or more foods while having active symptoms, and 74% continued to avoid 1 or more foods even in the absence of symptoms. Patients with a positive ARFID risk screen were significantly more likely to be at risk for malnutrition (60.7% vs 15.8%; P < .01)

Related blog post:

Afraid to Eat -Could be “Avoidant Restrictive Food Intake Disorder”

Prevalence of Avoidant/Restrictive Food Intake Disorders in Pediatric Neurogastroenterology

HB Murray et al. JPGN 2022; 74: 588-592. Prevalence and Characteristics of Avoidant/Restrictive Food Intake Disorder in Pediatric Neurogastroenterology Patients

Associated commentary by SB Oliveira, A Kaul: Invited Commentary Re: Prevalence and Characteristics of Avoidant/ Restrictive Food Intake Disorder in Pediatric Neurogastroenterology Patients

This was a retrospective study with 129 consecutive neurogastroenterology patients. Key findings:

  • Eleven cases (8%) met the full criteria for ARFID (DSM, 5th ed) and 19 cases (15%) had clinically significant avoidant/ restrictive eating behaviors with insufficient information for a definitive ARFID diagnosis
  • In a separate retrospective study, the same center published data on ARFID in a general pediatric population, showing 1.5% meeting the full criteria and 2.4% with some features (KT Eddy et al. Int J Eat Disord . 2015 Jul;48(5):464-70. Prevalence of DSM-5 avoidant/restrictive food intake disorder in a pediatric gastroenterology healthcare network)

The discussion notes that while elimination diets (eg. low FODMAPs diets) are frequently used for disorders of brain-gut interaction, they may increase the risk of ARFID. “Some children may develop fear of what will happen when they try foods again.”

The insightful commentary makes several useful points:

  • A retrospective study is not the best way to determine prevalence of ARFID particularly as many practitioners have limited familiarity and documentation may be inadequate
  • Nutritional rehabilitation can improve GI function. It has been shown that patients with anorexia nervosa have delayed gastric emptying which improved with refeeding. More broadly, it is often challenging to definitively determine the cause and effect in patients with malnutrition and gut dysmotility. (This is why I rarely obtain gastric emptying studies in patients with poor nutritional status)

My take: ARFID can be difficult to manage and is important to consider in our patient population, and probably even more so in patients seen in neurogastroenterology programs. The exact prevalence of ARFID in these programs is uncertain and prospective studies are needed.

Related blog post: